Nur Amalina Md Isa, Arun V Krishnan, Alessandro S Zagami, Shyam S Tummanapalli, Katherine Spira, Eric B Papas, Azadeh Tavakoli, Maria Markoulli
{"title":"A randomized crossover trial: The impact of ocular lubrication on migraine severity in persons with dry eye disease and migraine.","authors":"Nur Amalina Md Isa, Arun V Krishnan, Alessandro S Zagami, Shyam S Tummanapalli, Katherine Spira, Eric B Papas, Azadeh Tavakoli, Maria Markoulli","doi":"10.1097/OPX.0000000000002241","DOIUrl":null,"url":null,"abstract":"<p><strong>Significance: </strong>Significant associations in the epidemiologic and clinical features between migraine and dry eye syndrome suggest that both conditions are comorbid. A potentially overlapping pathophysiological mechanism further indicates a connection between the two conditions. This study highlights the clinical implications of treating dry eye disease on migraine.</p><p><strong>Purpose: </strong>This study aimed to investigate the impact on migraine severity of treating dry eye disease in migraine patients using ocular lubricants.</p><p><strong>Methods: </strong>A randomized, double-masked, crossover trial was conducted on 24 participants with both migraine and dry eye disease. They received either Systane Hydration UD (Alcon, Fort Worth, TX) or saline eye drops (NeilMed, Santa Rosa, CA) four times per day for 4 weeks each, with a 2-week washout period between treatments. Migraine severity was assessed using the Headache Impact Test 6 (HIT-6) and Migraine Disability Assessment questionnaires. Dry eye disease was evaluated using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire 5 (DEQ-5), tear breakup time, tear osmolarity, and corneal surface integrity. Outcomes were assessed at baseline and after using the first and then second drops.</p><p><strong>Results: </strong>Ocular lubrication was significantly associated with reduced migraine severity and dry eye disease. The HIT-6 score was reduced from baseline when using Systane Hydration UD (mean change, ∆ = -3.0, p=0.01) and saline (∆ = -3.9, p=0.002). Dry eye disease symptoms and corneal staining were reduced when using Systane Hydration UD (OSDI ∆ = -8.3, p=0.004; DEQ-5 ∆ = -2.1, p=0.004; corneal staining ∆ = -2.2, p=0.001) and saline (OSDI ∆ = -6.4, p=0.03; DEQ-5 ∆ = -1.5, p=0.03; corneal staining ∆ = -1.5, p=0.005).</p><p><strong>Conclusions: </strong>When migraine and dry eye disease coexist, successfully treating dry eye disease reduces the severity of migraine, as measured by HIT-6.</p>","PeriodicalId":19649,"journal":{"name":"Optometry and Vision Science","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Optometry and Vision Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/OPX.0000000000002241","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Significance: Significant associations in the epidemiologic and clinical features between migraine and dry eye syndrome suggest that both conditions are comorbid. A potentially overlapping pathophysiological mechanism further indicates a connection between the two conditions. This study highlights the clinical implications of treating dry eye disease on migraine.
Purpose: This study aimed to investigate the impact on migraine severity of treating dry eye disease in migraine patients using ocular lubricants.
Methods: A randomized, double-masked, crossover trial was conducted on 24 participants with both migraine and dry eye disease. They received either Systane Hydration UD (Alcon, Fort Worth, TX) or saline eye drops (NeilMed, Santa Rosa, CA) four times per day for 4 weeks each, with a 2-week washout period between treatments. Migraine severity was assessed using the Headache Impact Test 6 (HIT-6) and Migraine Disability Assessment questionnaires. Dry eye disease was evaluated using the Ocular Surface Disease Index (OSDI), Dry Eye Questionnaire 5 (DEQ-5), tear breakup time, tear osmolarity, and corneal surface integrity. Outcomes were assessed at baseline and after using the first and then second drops.
Results: Ocular lubrication was significantly associated with reduced migraine severity and dry eye disease. The HIT-6 score was reduced from baseline when using Systane Hydration UD (mean change, ∆ = -3.0, p=0.01) and saline (∆ = -3.9, p=0.002). Dry eye disease symptoms and corneal staining were reduced when using Systane Hydration UD (OSDI ∆ = -8.3, p=0.004; DEQ-5 ∆ = -2.1, p=0.004; corneal staining ∆ = -2.2, p=0.001) and saline (OSDI ∆ = -6.4, p=0.03; DEQ-5 ∆ = -1.5, p=0.03; corneal staining ∆ = -1.5, p=0.005).
Conclusions: When migraine and dry eye disease coexist, successfully treating dry eye disease reduces the severity of migraine, as measured by HIT-6.
期刊介绍：
Optometry and Vision Science is the monthly peer-reviewed scientific publication of the American Academy of Optometry, publishing original research since 1924. Optometry and Vision Science is an internationally recognized source for education and information on current discoveries in optometry, physiological optics, vision science, and related fields. The journal considers original contributions that advance clinical practice, vision science, and public health. Authors should remember that the journal reaches readers worldwide and their submissions should be relevant and of interest to a broad audience. Topical priorities include, but are not limited to: clinical and laboratory research, evidence-based reviews, contact lenses, ocular growth and refractive error development, eye movements, visual function and perception, biology of the eye and ocular disease, epidemiology and public health, biomedical optics and instrumentation, novel and important clinical observations and treatments, and optometric education.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
